Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

This article was originally published here

“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid cells in

The post Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply